Drug Spending on Accelerated Approval Indications Subsequently Withdrawn From the Market

This cross-sectional study examines spending on drugs with indications approved by the US Food and Drug Administration and withdrawn from the market from 2015 to 2024.

Corresponding Author: Stacie B. Dusetzina, PhD, Department of Health Policy, Vanderbilt University School of Medicine, 2525 West End Ave, Ste 1209, Nashville, TN 37203 (s.dusetzina@vanderbilt.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.